PTI is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Pharmaceutical Regulatory Affairs in China

21 - 29 September 2020

New LIVE Online Academy


In light of the uncertain times we’re facing at the moment, gain real-time access to a subject matter expert delivering online training in a structured virtual classroom environment. 

Live online academies are virtual versions of some of our most popular face-to-face courses, delivered in bitesize sessions of 1.5-2 hours online.

All sessions will be recorded and uploaded to your virtual learning environment which you will get access to for a month. As part of this you will also be able to access a forum where you can communicate with your trainer and peers on the course.

Delegates will receive login instructions within a week of the course start date. If you have any questions please contact [email protected].

For more information and a comparison with other digital study modes, download the digital training guide.

Develop or market your drug in China more effectively with a deep understanding of the Chinese pharmaceutical regulatory landscape. In 2015 China’s pharmaceutical sector underwent significant regulatory reforms to align with EMA & FDA requirements, making the Chinese market one of the biggest pharmaceutical markets in the world. The reforms included clinical trial approval time being cut from 2 years to 60 days and the NMPA becoming a member of ICH.

During this course, you will learn fundamental Chinese regulatory requirements for pharmaceuticals and how they relate to the country’s economic and cultural background. Guided by our expert course leader you will discover best practices for registering new drugs and discuss the likely impact of the US – China Trade War on market access and drug development.

  • Understand how China’s cultural and economic background has impacted pharmaceutical regulations
  • Learn about reforms to legislation in China and the reasons behind the changes, including the development of the NMPA and the move to the 60-day clinical trial approval time
  • Learn best practices for successfully registering pharmaceutical products in China and the challenges which coincide with it
  • Familiarise yourself with the regulations governing biopharmaceuticals in China, evaluate the trends and gain an overview of CMC guidance
  • Understand the potential impact of the US-China Trade War on the Chinese pharmaceutical market

Two weeks before the course starts, delegates will be enrolled on to the online element of the Pharmaceutical Regulatory Affairs in China course. Through this they will have access to:

  • Bitesize introductory videos
  • Pre-reading materials
  • Trainer information
  • Discussion forum to interact with peers and the trainer

Delegates will continue to have access to the online element, after the course has finished, for networking and development purposes.

This course is applicable to anyone interested in accessing the Chinese pharmaceutical marketplace.

Relevant job titles may include: 

  • Heads of Department
  • Directors
  • Managers
  • Consultants

Relevant departments may include:

  • Project Management
  • Regulatory Affairs

Dr Ziqun Han

Dr Ziqun Han specialises in regulatory policy and intelligence for global pharmaceutical/biotech markets, with a focus on EU and Asia Pacific regions.

Dr Han has over 20 years of pharmaceutical/biotech drug development experience across a broad spectrum of therapeutic areas that include: Gene Therapy, Oncology, Neurology, immunology and Virology. In the past 10 years, Dr Han focused on helping leading global pharmaceutical/biotech companies understand global regulatory developments, and efficiently utilised those changes to shape regulatory strategies and product development. She has also been actively engaged with numerous trade associations and proactively advocates regulatory reforms to key regulators.

Dr Han’s educational credentials include a Bachelor of Medicine degree from the Capital University of Medical Science in Beijing, a PhD in Molecular Endocrinology from Imperial College, London and an Executive MBA from Imperial College, London.


We're looking forward to welcoming our attendees and expert course leaders at Pharmaceutical Regulatory Affairs in China in London in March.
Our number one priority is the safety of our delegates and colleagues, and there are always measures in place at our venues to safeguard your health and safety. There are extra measures in place for 2020 in light of developments with COVID-19.
Book with total confidence – click here to be fully assured on how your booking rights are protected.

You may also be interested in...